Taiwan-based CDMO Bora Pharma to pay up to $210M for Upsher-Smith to expand into the US

Tai­wan-head­quar­tered CD­MO Bo­ra Phar­ma­ceu­ti­cals is buy­ing gener­ic man­u­fac­tur­er Up­sh­er-Smith Lab­o­ra­to­ries for up to $210 mil­lion to ex­pand op­er­a­tions in­to the US for the first time.

“This is a sig­nif­i­cant mile­stone for Bo­ra Group, mark­ing the most crit­i­cal ex­pan­sion of Bo­ra’s pres­ence in the US mar­ket,” Bo­ra chair­man and CEO Bob­by Sheng said in a state­ment on Tues­day.

Bo­ra will gain Up­sh­er-Smith’s two man­u­fac­tur­ing fa­cil­i­ties in Ply­mouth and Maple Grove, MN, which can man­u­fac­ture a range of prod­uct forms, in­clud­ing oral solids, top­i­cal pow­ders and liq­uids. The sites al­so have pack­ag­ing ca­pa­bil­i­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.